Retrophin, Inc.

Retrophin, Inc.

Retrophin, Inc.

Overview
Date Founded

2008

Headquarters

3721 Valley Centre Drive, Suite 200, San Diego, CA, 92130, USA

Type of Company

Public

Employees (Worldwide)

214

Industries

Biotechnology
Hospitals & Patient Services
Pharmaceuticals
Medical Support Services

Company Description

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Contact Data
Trying to get in touch with decision makers at Retrophin, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Chief Financial & Accounting Officer

Senior Vice President, General Counsel & Corporate Secretary

Chief Medical Officer

Senior Vice President, Head-Research & Development

Executive Director Business de

Senior Director, Investor Relations

Director

AR Coordinator

Director of Medical Strategy

Board of Directors

Founder & Chief Executive Officer at GL Biomed

President, Chief Executive Officer & Director at Atreca, Inc.

Chief Medical Officer at Merck & Co., Inc.

Chief Executive Officer at Array BioPharma Inc.

Chief Scientific Officer & Director at ActivX Biosciences, Inc.

Professional at Fate Therapeutics, Inc.

Chief Executive Officer at Kyalin Biosciences, Inc.

Vice Chairman & Chief Executive Officer at Intec Pharma Ltd.

President & Chief Executive Officer at Retrophin, Inc.

Professional at Valneva SE

Paths to Retrophin, Inc.
Potential Connections via
Relationship Science
You
Retrophin, Inc.
Owners & Shareholders
Details Hidden

SCM employs a fundamentals-based, value-driven investment approach across four strategies: a long-short equity strategy managed with the discipline of market neutrality, a long-short equity strategy managed with net long exposure, a long-only equity strategy and a long-short health care focused strategy. The firm seeks to identify investments primarily in publicly-traded equities (on both US and non-US exchanges), including IPOs, but may also include options, derivatives and bonds that they believe will increase in value (or at least maintain their value) even in a falling market, and conversely to identify and sell short stocks that they believe will drop in value (or at least under-perform) regardless of the industry and the market's overall direction. The long portfolio focuses on dynamic companies protected by low valuations relative to free cash flow, strong cash positions or valuable intellectual property and sensible business models. The short portfolio selects companies that SCM determines are not only overvalued, but also fundamentally flawed because of the poor prospects of their products or services. The research process combines examining publicly available financial data and conducting in-depth proprietary field research.

Details Hidden

Consonance Capital Management's (CCM) funds seek to deliver exceptional, uncorrelated risk adjusted returns. CCM seeks to meet this objective by focusing on investment opportunities in the publicly traded stocks of healthcare companies. The firm invests in all sub-sectors of the healthcare sector including healthcare information technology, managed care, pharmaceuticals, specialty pharmaceuticals, commercial stage biotechnology, healthcare facilities and services, medical devices and supplies, diagnostics and consumer-based healthcare companies.CCM believes the public healthcare market lends itself to an active long/short strategy. The firm focuses on creating long and short portfolios driven by the opportunity for absolute return and alpha creation. The funds also invest in other types of securities and may use a variety of investment techniques to generate profit and/or control risk. These may include participating in swaps, buying or selling futures contracts, purchasing and writing options and other derivative contracts, purchasing or selling debt instruments, and trading on margin by borrowing funds and pledging securities as collateral. CCM invests primarily in healthcare companies in the US, and on an opportunistic basis in the rest of the world.^

Details Hidden

Perceptive Advisors focuses on investment opportunities in healthcare, with an emphasis on biotechnology. The firm believes that significant opportunities exist in biotechnology due to pervasive underlying market inefficiencies and volatility. Perceptive Advisors advises two separate master-feeder private fund structures.The Perceptive Life Sciences Funds invest in the equities of growth healthcare companies and value plays, with an emphasis on biotechnology. Perceptive Advisors seeks to identify opportunities to exploit relative value disparities and inefficiencies that exist on both the long and short side of the market. They focus on a universe of about 300 smaller, more inefficiently priced companies which are underfollowed by Wall Street biotechnology analysts. Hedging strategies using long and short equity positions, equity options, and index options are used in an attempt to reduce and control risk.The Perceptive Credit Opportunity Fund seeks to achieve superior risk-adjusted returns by investing in senior secured loans and other debt and debt-related instruments issued by small- and mid-cap publicly traded companies and privately-held emerging growth companies primarily in the healthcare and related industries. The fund's investments may be originated by the fund or in collaboration with a syndicate of other credit investors. Most of the fund's investments will be structured as directly originated loans to healthcare companies.Perceptive Advisors also advises two separate accounts. The investment strategies of the separate accounts are substantially similar to those of the Perceptive Life Sciences Fund, though the separate accounts may take more concentrated positions and use a higher degree of leverage.

Recent Transactions
Details Hidden

Retrophin, Inc. issued Common Stock

Details Hidden

Turing Pharmaceuticals AG purchases Retrophin, Inc. /Non-Core Assets from Retrophin, Inc.

Details Hidden

Retrophin, Inc. purchases Clinuvel Pharmaceuticals Ltd.

Transaction Advisors
Underwriter

Advised onRetrophin, Inc. issued Common Stock

Auditor

Advised onRetrophin, Inc. issued Common Stock

Underwriter

Advised onRetrophin, Inc. issued Common Stock

Senior Managing Director

Advised onRetrophin, Inc. issued Common Stock

Managing Director

Advised onRetrophin, Inc. issued Common Stock

Legal Advisor

Advised onRetrophin, Inc. issued Common Stock

Advisors & Consultants
Consultant

Former Chief Medical Officer & Executive Vice President of Research & Development at Retrophin, Inc.

Legal Advisor

Counsel at Skadden, Arps, Slate, Meagher & Flom LLP

Consultant

Former Vice President, Clinical Development & Medical Affairs at Genzyme Corp.

Clients

Dohmen Life Science Services LLC provides health care services. It offers outsourcing services to biopharma and medical devices. The firm's services include patient, channel support, compliance and technology services. The company was founded by Cynthia LaConte in 2014 is headquartered in Milwaukee, WI.

Key Stats and Financials As of 2018
Market Capitalization
$817M
Total Enterprise Value
$661M
Earnings Per Share
$-2.54
Revenue
$164M
Net Profit
$-103M
EBITDA
$-50M
Debt TEV
0.33x
Enterprise Value Sales
4.02x
TEVNet Income
-6.44x
Total Equity
$318M
Total Debt
$218M
EBITDAMargin
-30.46%
Three Year Compounded Annual Growth Rate Of Revenue
18.03%
Investments
Details Hidden

Perlara PBC manufactures orphan drugs. It solves the unmet medical needs of orphan disease patients with a scalable drug candidate generator that leaves no mutation behind. The company was founded by Ethan Perlstien in February 2014 and is headquartered in San Francisco, CA.

Suppliers
Ligand Pharmaceuticals, Inc. Medical Support Services | LA JOLLA , CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Nexgen Pharma (TM), Inc. Pharmaceuticals | Irvine, CA

Nexgen Pharma (TM), Inc. manufactures and develops drugs. The firm also offers pharmaceutical product development, dietary supplement formulation, process and cleaning validation and many other services. The company was founded by J. W. Wigelsworth in 1925 and is headquartered in Irvine, CA.

Mission Pharmacal Co. Pharmaceuticals | San Antonio, TX

Mission Pharmacal Co. manufactures pharmaceutical products. Its products include Flowtuss, Hycofenix, Thera-Gesic, Oncovite, Maxilube, Heat Guard, Foseree and Texacort. The company's capabilities include research and development, laboratory, manufacturing, packaging, warehousing and distribution and international services. Mission Pharmacal was founded in 1946 by H. N. Walsdorf and is headquartered in San Antonio, TX.

Competitors
Pfizer, Inc. Pharmaceuticals - New York, NY

Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Novartis AG Pharmaceuticals - Basel, BS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following four segments: Innovative Medicines, Alcon, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Alcon segment researches, develops, manufactures, distributes and sells eye care devices and vision care. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Retrophin, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Retrophin, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Retrophin, Inc..
  • be_ixf; php_sdk; php_sdk_1.4.15
  • https://relationshipscience.com/organization/retrophin-inc-91067877
  • https://relationshipscience.com/organization/retrophin-inc-91067877